北京英诺特生物技术股份有限公司关于股份回购实施结果暨股份变动的公告

Core Viewpoint - The company has successfully completed its share repurchase plan, acquiring a total of 2,112,740 shares, which represents 1.5483% of its total share capital, with a total expenditure of approximately RMB 78 million [4][5]. Group 1: Share Repurchase Approval and Plan - On August 2, 2024, the company’s board approved a share repurchase plan, allowing for a maximum repurchase price of RMB 50.00 per share, with a total repurchase amount between RMB 50 million and RMB 100 million [2]. - Following the annual equity distribution for 2024, the maximum repurchase price was adjusted to RMB 49.45 per share [3]. Group 2: Implementation of Share Repurchase - The first share repurchase occurred on September 6, 2024, with ongoing disclosures of repurchase progress in accordance with relevant regulations [4]. - The repurchase was executed through the Shanghai Stock Exchange, with the highest transaction price at RMB 45.37 per share and the lowest at RMB 28.62 per share [4]. Group 3: Financial Impact and Shareholder Rights - The funds used for the repurchase were from the company’s own resources, ensuring no significant impact on its operational activities or financial status [5]. - The repurchased shares will not have voting rights or profit distribution rights during the holding period and will be used for future employee stock ownership plans or equity incentives [5].